2025
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgery
2023
Associations amongst genes, molecules, cells, and organs in breast cancer metastasis
Nathanson S, Dieterich L, Zhang X, Chitale D, Pusztai L, Reynaud E, Wu Y, Ríos-Hoyo A. Associations amongst genes, molecules, cells, and organs in breast cancer metastasis. Clinical & Experimental Metastasis 2023, 41: 417-437. PMID: 37688650, DOI: 10.1007/s10585-023-10230-w.Peer-Reviewed Original ResearchBreast cancer metastasisBreast cancerCancer metastasisOutcomes of patientsAnti-tumor immunityHope of cureAggressive therapyMultiple metastasesAggressive treatmentBone metastasesLymph nodesSystemic metastasesMorphologic subtypesClinical oncologistsMetastasisInternal visceraAssists cliniciansLymphatic endothelial cellsPatientsEndothelial cellsHealth SymposiumBasic scientistsMolecular expressionCancerMolecular aspects
2022
Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer.
Kowalchuk R, Niranjan A, Hess J, Antonios J, Zhang M, Braunstein S, Ross R, Pikis S, Deibert C, Lee C, Yang H, Langlois A, Mathieu D, Peker S, Samanci Y, Rusthoven C, Chiang V, Wei Z, Lunsford L, Trifiletti D, Sheehan J. Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer. Journal Of Neurosurgery 2022, 138: 1608-1614. PMID: 36433878, DOI: 10.3171/2022.10.jns221900.Peer-Reviewed Original ResearchTriple-negative breast cancerLocal tumor progressionStereotactic radiosurgeryBreast cancerOverall survivalMetastatic lesionsPerformance statusLocal controlTriple-negative breast cancer metastasisMedian Karnofsky performance statusTumor progressionWhole-brain radiation therapyFavorable performance statusMedian margin dosePrior stereotactic radiosurgerySymptomatic radiation necrosisKarnofsky performance statusIntracranial metastatic diseaseRetrospective chart reviewLocal tumor controlBreast cancer metastasisIntracranial metastatic lesionsMargin doseMultiinstitutional cohortBrain metastasesFluid shear stress enhances proliferation of breast cancer cells via downregulation of the c-subunit of the F1FO ATP synthase
Park HA, Brown SR, Jansen J, Dunn T, Scott M, Mnatsakanyan N, Jonas EA, Kim Y. Fluid shear stress enhances proliferation of breast cancer cells via downregulation of the c-subunit of the F1FO ATP synthase. Biochemical And Biophysical Research Communications 2022, 632: 173-180. PMID: 36209586, PMCID: PMC10024463, DOI: 10.1016/j.bbrc.2022.09.084.Peer-Reviewed Original ResearchLCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nature Cancer 2022, 3: 355-370. PMID: 35301507, DOI: 10.1038/s43018-022-00339-4.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerCancer stem cellsLigand-dependent corepressorTumor immunogenicityBreast cancerImmune checkpoint blockadeBreast cancer metastasisICB efficacyICB resistanceLCoR expressionClinical responsePresentation machineryImmune escapeAPM genesPreclinical modelsTherapy resistanceCancer metastasisPromising targetOvercame resistanceIFNRNA therapyCancerImmunogenicitySignaling-independent mannerStem cellsCECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Science Translational Medicine 2022, 14: eabf5473. PMID: 35108062, PMCID: PMC9003667, DOI: 10.1126/scitranslmed.abf5473.Peer-Reviewed Original ResearchConceptsBreast cancer metastasisReticuloendotheliosis viral oncogene homolog ACancer metastasisImmune suppressionM2 macrophagesWorse metastasis-free survivalMetastatic breast cancerMetastasis-free survivalV-rel avian reticuloendotheliosis viral oncogene homolog ACancer-related deathPrimary breast tumorsMultiple mouse modelsNF-κB signalingImmunocompetent settingNuclear factor-κB family membersMetastasis-promoting genesDistant metastasisMetastatic sitesPrimary tumorEffective therapyBreast cancerMetastasis treatmentMouse modelBreast tumorsMetastasis
2021
Utilizing Radiation Dose Maps to Predict Local Failure Following Stereotactic Radiation of Brain Metastases
Kutuk T, Pandey S, Mills M, Abdalah M, Stringfield O, Latifi K, Robinson T, Ahmed K, Raghunand N. Utilizing Radiation Dose Maps to Predict Local Failure Following Stereotactic Radiation of Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e570-e571. DOI: 10.1016/j.ijrobp.2021.07.1540.Peer-Reviewed Original ResearchInflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction
Back J, Nguyen MN, Li L, Lee S, Lee I, Chen F, Gillinov L, Chung YH, Alder KD, Kwon HK, Yu KE, Dussik CM, Hao Z, Flores MJ, Kim Y, Ibe IK, Munger AM, Seo SW, Lee FY. Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction. Bone Research 2021, 9: 43. PMID: 34588427, PMCID: PMC8481290, DOI: 10.1038/s41413-021-00158-w.Peer-Reviewed Original ResearchCancer-induced bone destructionBreast cancer cellsOsteolytic breast cancerBone homeostasisCancer growthCancer cellsBone destructionInflammatory osteolysisBreast cancerBreast cancer-induced bone destructionOsteolytic breast cancer metastasesPromising adjuvant therapyERK1/2 activationMEK1 expressionBreast cancer metastasisMetastatic breast cancer cellsActivation of pERK1/2Inflammatory conversionAdjuvant therapyPathological fracturesHuman pathological specimensBone microenvironmentPathological specimensSkeletal diseasePathway inhibitorInduction of interferon signaling and allograft inflammatory factor 1 in macrophages in a mouse model of breast cancer metastases
Zheng W, Zhao D, Zhang H, Chinnasamy P, Sibinga N, Pollard JW. Induction of interferon signaling and allograft inflammatory factor 1 in macrophages in a mouse model of breast cancer metastases. Wellcome Open Research 2021, 6: 52. PMID: 33824914, PMCID: PMC8008350, DOI: 10.12688/wellcomeopenres.16569.2.Peer-Reviewed Original ResearchGene expression programsDifferent gene expression profilesGene-targeted mouse modelsGene expression profilesFactor 1Interferon-responsive genesAllograft inflammatory factor-1Metastatic breast cancer cellsExpression programsInflammatory factor-1Functional validationExpression profilesActivated pathwaysMetastatic growthC57BL6/J backgroundBreast cancer cellsSignificant enrichmentFunctional relevanceInterferon SignalingResident alveolar macrophagesBreast cancer metastasisQRT-PCRStrong upregulationCancer metastasisHuman macrophagesPharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β
Pradhan A, Maji S, Bhoopathi P, Talukdar S, Mannangatti P, Guo C, Wang X, Cartagena L, Idowu M, Landry J, Sarkar D, Emdad L, Cavenee W, Das S, Fisher P. Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2103180118. PMID: 34016751, PMCID: PMC8166168, DOI: 10.1073/pnas.2103180118.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorChemokine CCL11Chemokine CCL17FemaleGene Expression Regulation, NeoplasticHumansInterleukin-10Interleukin-1alphaInterleukin-1betaInterleukin-23 Subunit p19Interleukin-5Lung NeoplasmsMiceMice, Inbred BALB COxadiazolesPyrimidinesSignal TransductionSynteninsT-Lymphocytes, CytotoxicTumor BurdenXenograft Model Antitumor AssaysConceptsMDA-9/SynteninMyeloid-derived suppressor cell differentiationSuppressor cell differentiationCancer cellsAdvanced disease stageAggressive breast cancerCytotoxic T lymphocytesMetastatic nodule formationBreast cancer metastasisBreast cancer pathogenesisMda-9/syntenin expressionCancer cell metastasisDirect therapeutic targetsCancer cell linesDiverse cancer cell linesPatient survivalDisease stageIL-1βSyndecan binding proteinBreast cancerInvasive cancer cellsT lymphocytesTherapeutic targetSmall molecule inhibitorsAdvanced stageInduction of interferon signaling and allograft inflammatory factor 1 in macrophages in a mouse model of breast cancer metastases
Zheng W, Zhao D, Zhang H, Chinnasamy P, Sibinga N, Pollard J. Induction of interferon signaling and allograft inflammatory factor 1 in macrophages in a mouse model of breast cancer metastases. Wellcome Open Research 2021, 6: 52. DOI: 10.12688/wellcomeopenres.16569.1.Peer-Reviewed Original ResearchGene expression programsDifferent gene expression profilesGene-targeted mouse modelsGene expression profilesFactor 1Interferon-responsive genesAllograft inflammatory factor-1Metastatic breast cancer cellsExpression programsInflammatory factor-1Functional validationExpression profilesActivated pathwaysMetastatic growthC57BL6/J backgroundBreast cancer cellsSignificant enrichmentFunctional relevanceInterferon SignalingResident alveolar macrophagesBreast cancer metastasisQRT-PCRStrong upregulationCancer metastasisHuman macrophages
2020
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesCancer liver metastasesSystemic chemotherapyHepatic resectionLiver metastasesAblative therapyProlonged disease-free intervalDisease-free intervalBetter overall survivalLong-term outcomesLocal-regional therapyEffective systemic chemotherapyBreast cancer metastasisLimited diseaseOverall survivalRegional therapySurgical managementSurgery benefitMultidisciplinary settingPatientsCancer metastasisMetastasisTherapyResectionChemotherapy
2019
Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports 2019, 9: 8572. PMID: 31189943, PMCID: PMC6561945, DOI: 10.1038/s41598-019-42784-9.Peer-Reviewed Original ResearchConceptsBreast cancer skin metastasesBreast cancer metastasisSkin metastasesImmune responsePost-treatment tumor samplesCancer metastasisReceptor 7 agonistStrong T-helperDurable clinical responsesImmune effector functionsBasal cell carcinomaRobust immune responseTopical imiquimodClinical responseT helperTumor rejectionCell carcinomaCytotoxic functionTranscriptomic profilesTumor regressionClinical trialsAntigen presentationT cellsImiquimodTumor destructionRetraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling
Mansour M, Haupt S, Chan A, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano E, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang Y, Yap A, Fox S, Bernard O, Anderson R, Haupt Y. Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research 2019, 79: 3008-3008. PMID: 31160311, DOI: 10.1158/0008-5472.can-19-1133.Peer-Reviewed Original ResearchBreast cancer metastasis
2016
The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling
Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y. The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research 2016, 76: 4236-4248. PMID: 27231202, DOI: 10.1158/0008-5472.can-15-1553.Peer-Reviewed Original ResearchConceptsBreast cancer patientsPoor prognosisCancer patientsBreast cancerBreast cancer-related deathsSuppresses breast cancer metastasisMetastatic breast cancerCancer-related deathBreast cancer metastasisBasal breast cancerBreast cancer invasivenessSteroid hormone receptorsMetastatic diseaseCurrent therapiesSecondary tumorsTherapeutic approachesTumor cell migrationCancer metastasisPatientsCancer invasivenessHormone receptorsMetastasisMajor causeHigh expressionE3 ubiquitin protein ligase
2015
Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival
Lu L, Zeng H, Gu X, Ma W. Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival. Breast Cancer Research And Treatment 2015, 151: 491-500. PMID: 25957595, DOI: 10.1007/s10549-015-3416-1.Peer-Reviewed Original ResearchConceptsBreast cancer survivalCancer survivalBreast cancerTumor cellsDisease-specific deathBreast cancer recurrencePotential prognostic biomarkerBreast cancer metastasisEpithelial-mesenchymal transitionHigh metastatic potentialFurther metastasesPatient survivalCancer recurrencePrognostic biomarkerTherapeutic targetSurvival analysisMetastatic potentialCancer metastasisMajor causeHigh expressionEpithelial cellsCancerRole of plakoglobinDouble-edged functionSurvival
2014
Role of PTHrP in Mammary Gland Development and Breast Cancer
Hiremath M, Wysolmerski J. Role of PTHrP in Mammary Gland Development and Breast Cancer. Clinical & Translational Metabolism 2014, 12: 178-189. DOI: 10.1007/s12018-014-9170-9.Peer-Reviewed Original ResearchRole of PTHrPBreast cancerMammary glandOsteolytic bone lesionsPrimary breast cancerBreast cancer metastasisNormal mammary glandMammary cell fateMammary gland developmentMaternal calciumBone lesionsPrimary tumorMineral metabolismEmbryonic mammary developmentBreast pathogenesisNeonatal bonePTHrPMammary developmentCancer metastasisGland developmentSupply of calciumCancerGlandProtein signalingBoneHistone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis
Cao J, Liu Z, Cheung WK, Zhao M, Chen SY, Chan SW, Booth CJ, Nguyen DX, Yan Q. Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis. Cell Reports 2014, 6: 868-877. PMID: 24582965, PMCID: PMC4014129, DOI: 10.1016/j.celrep.2014.02.004.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCell Line, TumorDisease ProgressionEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHistone DemethylasesHumansMaleMammary Neoplasms, ExperimentalMiceMice, Inbred NODMice, SCIDMice, TransgenicNeoplasm MetastasisRetinol-Binding Proteins, CellularTransfectionConceptsHistone demethylase RBP2MMTV-neu transgenic miceHuman breast cancer cellsMajor clinical challengeBreast cancer metastasisBreast cancer progressionBreast cancer cellsClinical challengeBreast cancer gene expression data setsTherapeutic targetingTransgenic miceMetastasisMetastatic progressionPutative mediatorsTumor progressionCancer metastasisCancer treatmentCancer progressionTumor metastasisTumor formationCancer cellsProgressionAberrant epigenetic modificationsMetastasis genesMice
2013
Intramedullary metastasis in breast cancer – A comprehensive literature review
Rostami R, Safarpour D, Tavassoli FA, Jabbari B. Intramedullary metastasis in breast cancer – A comprehensive literature review. Journal Of The Neurological Sciences 2013, 332: 16-20. PMID: 23778028, DOI: 10.1016/j.jns.2013.05.032.Peer-Reviewed Original ResearchConceptsCerebrospinal fluidIntramedullary metastasisBrain metastasesTrue incidenceTreatment strategiesBreast cancerMedline/Pub MedBrown-Sequard syndromeConcurrent brain metastasisThoracic cord lesionsBreast cancer metastasisMagnetic resonance imagingBreast cancer diagnosisBladder dysfunctionBreast metastasisCord lesionsThoracic cordBetter prognosisClinical symptomsLung metastasesUnfavorable prognosisLonger survivalSpinal cordTumor markersMetastasis
2012
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer
Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research And Treatment 2012, 137: 631-636. PMID: 23242617, PMCID: PMC3867793, DOI: 10.1007/s10549-012-2374-0.Peer-Reviewed Original ResearchConceptsBreast cancerBone metastasesStage IP1NP levelsSerum levelsIL-6Procollagen type I N-terminal propeptideType I N-terminal propeptideCox proportional hazards regression analysisProportional hazards regression analysisEarly-stage breast cancerPoor OS rateSerum P1NP levelsKaplan-Meier methodOverall survival rateHazards regression analysisLower overall survivalBone metastasis developmentBreast cancer metastasisBlood sample collectionN-terminal propeptideAdvanced diseaseOverall survivalOS ratesSerum P1NP
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply